{
}
Dr. Reddy’s Laboratories reported a strong Q2FY25 performance, with US sales growing 15.6% YoY to USD 445 million, driven by gRevlimid and a robust vaccine portfolio in India. The company’s outlook remains positive, supported by recent acquisitions and new product launches, prompting a HOLD rating with a target price of INR 1,270.
Regeneron Pharmaceuticals, Inc. has received a buy rating from UBS, highlighting its focus on developing treatments for eye diseases, inflammatory conditions, and cancer. The company's net sales are primarily derived from product sales (56.6%) and collaboration agreements (40.4%), with significant partnerships with Sanofi, Bayer, and Roche. As of the end of 2022, Regeneron boasts a clinical development portfolio of approximately 35 products.
Regeneron Pharmaceuticals, Inc. has received a buy rating from UBS, highlighting its focus on developing treatments for eye diseases, inflammatory conditions, and cancer. The company's net sales are primarily derived from product sales (56.6%) and collaboration agreements (40.4%), with significant partnerships with Sanofi, Bayer, and Roche. As of the end of 2022, Regeneron boasts a clinical development portfolio of approximately 35 products.
Evommune, a California biotech startup, has secured $115 million in Series C funding to advance its immune drug candidates, EVO756 and EVO301, targeting chronic immune conditions. The funding will support three Phase 2 trials, with results expected by the end of 2026. EVO756, an oral treatment for chronic skin hives, aims to be a first-in-class therapy, while EVO301 targets atopic dermatitis and shows promise in early testing.
Biogen raised its diluted earnings per share guidance for the year to $16.10-$16.60, driven by strong sales of new products like Leqembi, which generated $67 million in Q3, a 66% increase from the previous quarter. Despite this, total revenue is expected to decline in 2024, with ongoing challenges in its multiple sclerosis drug sales. The company is undergoing significant transformation under CEO Chris Viehbacher, focusing on cost-cutting and diversifying its research portfolio.
UBS has reiterated its buy recommendation for Sanofi, as reported by Cercle Finance. BOURSORAMA, acting solely as a distribution channel, emphasizes that the analysis is provided "as is" without any warranties, and the opinions expressed do not reflect its views. The institution maintains a conflict of interest management policy to ensure objectivity in its investment recommendations.
Sanofi reported a business EPS of 2.86 euros for Q3 2024, reflecting a 12.2% increase on a reported basis and 17.6% at constant exchange rates, with sales exceeding 13.4 billion euros, up 12.3%. UBS has reiterated its Buy recommendation, maintaining a target price of 110 euros, citing strong sales and early profitability gains expected for fiscal 2025. The company has also raised its 2024 outlook, anticipating business EPS growth in the low single-digit range.
UBS has reiterated its buy recommendation for Sanofi, as reported by Cercle Finance. BOURSORAMA, acting solely as a distribution channel, emphasizes that it has not influenced the analysis, which is provided for informational purposes only and carries no contractual value. The institution maintains a conflict of interest management policy to ensure objectivity in its investment recommendations.
Sanofi reported a business EPS of 2.86 euros for Q3 2024, reflecting a 12.2% increase on a reported basis and 17.6% at constant exchange rates, with sales exceeding 13.4 billion euros, up 12.3%. UBS has reiterated its Buy recommendation, maintaining a target price of 110 euros, citing strong sales and profitability gains expected for fiscal 2025. The company has also raised its 2024 outlook, anticipating business EPS growth at least in the low single digits.
The global pet healthcare market is projected to grow from $239.29 billion in 2023 to $255.96 billion in 2024, with a CAGR of 7.0%. Key drivers include an increasing pet population, advancements in veterinary care, and a focus on preventive health. By 2028, the market is expected to reach $353.66 billion, driven by trends such as pet humanization and economic prosperity.
Sanofi
Companies
| Symbol | SNY |
| Name | Sanofi |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Pharmaceuticals |
| Market | NASDAQ Global Select |
| Country | France |
| State | |
| City | Paris |
| Zipcode | 75008 |
| Website | http://www.sanofi.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Dr Reddy's Laboratories maintains hold rating with target price of 1270
09:04 06.11.2024
regeneron pharmaceuticals receives buy rating as it expands drug portfolio
United States Dollar
Bayer AG
Sanofi
Hoffmann-La Roche AG
Regeneron Pharmaceuticals, Inc.
DEU
FRA
USA
Roche
Bayer
Sanofi
Show more
16:08 01.11.2024
Regeneron Pharmaceuticals receives buy rating amid strong sales and collaborations
United States Dollar
Bayer AG
Sanofi
Hoffmann-La Roche AG
Regeneron Pharmaceuticals, Inc.
DEU
FRA
USA
Roche
Bayer
Sanofi
Show more
16:08 01.11.2024
Evommune secures 115 million dollars to advance immune drug development
United States Dollar
Regeneron Pharmaceuticals, Inc.
Incyte Corporation
Novartis AG
Celldex Therapeutics, Inc.
Sanofi
USA
Joe Biden
Luis Pena
Show more
16:05 31.10.2024
biogen raises earnings forecast amid strong sales of new products
United States Dollar
Biogen Inc.
Sanofi
USA
Brian Abrahams
Salim Syed
Chris Viehbacher
Michael Yee
Show more
15:15 30.10.2024
ubs maintains buy recommendation for sanofi amid market analysis
16:40 29.10.2024
Sanofi reports strong Q3 earnings prompting UBS to maintain buy rating
12:28 29.10.2024
ubs maintains buy rating on sanofi amid market analysis
12:25 29.10.2024
Sanofi reports strong Q3 earnings prompting UBS to maintain buy rating
12:25 29.10.2024
global pet healthcare market projected to reach 353 billion by 2028
Elanco Animal Health Incorporated
Norbrook Laboratories Ltd.
PETCO Animal Supplies Inc.
Phibro Animal Health Corporation
Royal Canin
Merck & Co., Inc.
VCA Animal Hospitals Inc.
IDEXX Laboratories, Inc.
Perrigo Company plc
Chewy, Inc.
Colgate-Palmolive Company
Mars Inc.
Trupanion, Inc.
Nestlé S.A.
Zoetis Inc.
Sanofi
Boehringer Ingelheim International GmbH
Vetoquinol S.A.
Ceva Sante Animale SA
General Mills, Inc.
USA
IND
AUS
FRA
DEU
BRA
IDN
JPN
RUS
GBR
KOR
CHN
Sanofi SA
Mars Inc.
General Mills Inc.
Nestle SA
Merck & Co Inc.
Show more
03:01 29.10.2024
Trending
Subcategory
Countries:
Companies:
Currencies:
People: